Yan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan Zhang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Chaoqun Wu
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China
2 shared publications - Hao Yang
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China
2 shared publications - Jianlan Cui
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China
2 shared publications - Lijuan Song
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China
2 shared publications - Wei Xu
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China
2 shared publications - Wenyan He
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China
2 shared publications
Latest Publications
- Open Access
Protein biomarkers for predicting incident carotid plaque: a nested case–control study in the ChinaHEART cohort with transportability assessment in the UK Biobank
Objectives: Carotid plaque is an early manifestation of atherosclerosis and is closely associated with the risk of myocardial ischaemia, ischaemic stroke and other atherosclerotic cardiovascular diseases (ASCVDs). To identify new protein biomarkers associated with carotid plaque, which will enhance early warning of ASCVDs Design: Nested case–control study within a prospective cohort, with external assessment of transportability in an independent population-based cohort. Participants and data sources: The development cohort is from China, which is a nationwide, community-based cohort and the external validation cohort is from the UK Biobank in the UK. In the development cohort, 292 participants without carotid plaque at baseline were included, comprising 145 incident cases and 147 matched controls selected based on age, sex, low-density lipoprotein cholesterol, systolic blood pressure, body mass index, smoking status and diabetes history. In the validation dataset, 30 800 participants without baseline cardiovascular disease were included from a large population-based cohort. Results: A total of 11 biomarkers, including thrombomodulin, intercellular cell adhesion molecule-3, P-selectin, growth differentiation factor-15, adiponectin, monocyte chemoattractant protein-1, IL-10, placental growth factor, tyrosine kinase receptor-2, vascular endothelial growth factor-D and vascular cell adhesion molecule-1, were selected by least absolute shrinkage and selection operator regression and used to construct a prediction model for the carotid plaque. The area under the receiver operator characteristic curve (AUC) of the eventual model is 0.761, and it showed good calibration capability graphically with a Brier score of 0.192. In the UK Biobank cohort, when these biomarkers were added to a traditional predictive model, a better predictive power was generated, with an AUC improvement of 0.021 (p<0.001, Delong test), Brier score of 0.093, a continuous net reclassification improvement of 0.259 (0.223–0.294, p<0.001) and an integrated discrimination improvement of 0.017 (0.015–0.019, p<0.001) relative to the traditional model. Conclusions: The identified protein biomarkers were used to predict carotid plaque and may provide modest incremental value for risk stratification beyond traditional risk factors. However, the findings should be interpreted with caution and further studies are needed to evaluate their clinical utility.
Open AccessProtein biomarkers for predicting incident carotid plaque: a nested case–control study in the ChinaHEART cohort with transportability assessment in the UK Biobank
Objectives: Carotid plaque is an early manifestation of atherosclerosis and is closely associated with the risk of myocardial ischaemia, ischaemic stroke and other atherosclerotic cardiovascular diseases (ASCVDs). To identify new protein biomarkers associated with carotid plaque, which will enhance early warning of ASCVDs Design: Nested case–control study within a prospective cohort, with external assessment of transportability in an independent population-based cohort. Participants and data sources: The development cohort is from China, which is a nationwide, community-based cohort and the external validation cohort is from the UK Biobank in the UK. In the development cohort, 292 participants without carotid plaque at baseline were included, comprising 145 incident cases and 147 matched controls selected based on age, sex, low-density lipoprotein cholesterol, systolic blood pressure, body mass index, smoking status and diabetes history. In the validation dataset, 30 800 participants without baseline cardiovascular disease were included from a large population-based cohort. Results: A total of 11 biomarkers, including thrombomodulin, intercellular cell adhesion molecule-3, P-selectin, growth differentiation factor-15, adiponectin, monocyte chemoattractant protein-1, IL-10, placental growth factor, tyrosine kinase receptor-2, vascular endothelial growth factor-D and vascular cell adhesion molecule-1, were selected by least absolute shrinkage and selection operator regression and used to construct a prediction model for the carotid plaque. The area under the receiver operator characteristic curve (AUC) of the eventual model is 0.761, and it showed good calibration capability graphically with a Brier score of 0.192. In the UK Biobank cohort, when these biomarkers were added to a traditional predictive model, a better predictive power was generated, with an AUC improvement of 0.021 (p<0.001, Delong test), Brier score of 0.093, a continuous net reclassification improvement of 0.259 (0.223–0.294, p<0.001) and an integrated discrimination improvement of 0.017 (0.015–0.019, p<0.001) relative to the traditional model. Conclusions: The identified protein biomarkers were used to predict carotid plaque and may provide modest incremental value for risk stratification beyond traditional risk factors. However, the findings should be interpreted with caution and further studies are needed to evaluate their clinical utility.
- Open Access
Forecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort
Background Cardiovascular disease (CVD) remains a significant public health challenge in China. This study aimed to project the burden of CVD from 2020 to 2030 using a nationwide cohort and to simulate the potential impact of various control measures on morbidity and mortality. Methods An agent-based model was employed to simulate annual CVD incidence and mortality from 2021 to 2030. The effects of different prevention and treatment interventions, modelled on international strategies, were also explored. Results The study included 106 259 participants. The annual CVD incidence rate is projected to increase from 0.74% in 2021 to 0.97% by 2030, with age-standardised and sex-standardised rates rising from 0.71% to 0.96%. CVD mortality is expected to rise from 0.39% in 2021 to 0.46% in 2024, after which it will stabilise at 0.44% by 2030. Community-based interventions and improved access to inpatient care are predicted to reduce the projected burden of CVD significantly. Conclusions The incidence of CVD in China is projected to increase steadily over the next decade, while mortality will plateau after 2024. Comprehensive interventions, including community-based screenings and enhanced healthcare access, could significantly mitigate the CVD burden. Trial registration number NCT02536456.
Open AccessForecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort
Background Cardiovascular disease (CVD) remains a significant public health challenge in China. This study aimed to project the burden of CVD from 2020 to 2030 using a nationwide cohort and to simulate the potential impact of various control measures on morbidity and mortality. Methods An agent-based model was employed to simulate annual CVD incidence and mortality from 2021 to 2030. The effects of different prevention and treatment interventions, modelled on international strategies, were also explored. Results The study included 106 259 participants. The annual CVD incidence rate is projected to increase from 0.74% in 2021 to 0.97% by 2030, with age-standardised and sex-standardised rates rising from 0.71% to 0.96%. CVD mortality is expected to rise from 0.39% in 2021 to 0.46% in 2024, after which it will stabilise at 0.44% by 2030. Community-based interventions and improved access to inpatient care are predicted to reduce the projected burden of CVD significantly. Conclusions The incidence of CVD in China is projected to increase steadily over the next decade, while mortality will plateau after 2024. Comprehensive interventions, including community-based screenings and enhanced healthcare access, could significantly mitigate the CVD burden. Trial registration number NCT02536456.